ClinConnect ClinConnect Logo
Search / Trial NCT03609580

Post-operative Urinary Retention (POUR) Following Thoracic Surgery

Launched by HACKENSACK MERIDIAN HEALTH · Jul 31, 2018

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Post Operative Urinary Retention Inability To Urinate Urinary Retentions Lung Cancer Va Ts Robotic Lung Surgery Lung Resections

ClinConnect Summary

This clinical trial is studying a common problem called post-operative urinary retention, which is when patients have trouble urinating after chest surgery. This issue often affects men over 50 and can make them feel uncomfortable and anxious, leading to longer hospital stays and the need for additional procedures, like inserting a catheter. To help prevent this problem, the trial is testing a medication called Flomax (Tamsulosin), which helps relax the prostate and improve urine flow. Participants will take Flomax daily starting a week before their surgery.

To be eligible for this study, men must be at least 50 years old and have a scheduled minimally invasive thoracic surgery. However, those who are already taking Flomax, have certain medical conditions, or have had prostate surgery in the past cannot join. Participants in the trial can expect to take the medication as directed and will be monitored for any effects on their ability to urinate after surgery. This study is currently recruiting, and it aims to make the recovery process more comfortable for patients undergoing these types of surgeries.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Males
  • ≥50 years old Planned surgical procedure of a minimally invasive thoracic surgical procedure (wedge resection, segmentectomy, lobectomy, pleural biopsy, or pleurodesis) Surgery scheduled more than 3 days from the time of consent
  • Exclusion Criteria:
  • Using Flomax already
  • Allergy to Flomax or sulfa drugs
  • Current use of alpha blockers or alpha agonists
  • Resting systolic blood pressure \<100
  • Orthostatic hypotension of \>20mm Hg (millimeters of mercury) Systolic and/or 10mm Hg diastolic pressure from sitting to standing (after 2 minutes of standing) as measured at the time of consent
  • Known diagnosis of congestive heart failure and valvular heart disease
  • History of prostate surgery (prostatectomy, trans-urethral resection)

About Hackensack Meridian Health

Hackensack Meridian Health is a leading healthcare organization based in New Jersey, dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent sponsor of clinical research, Hackensack Meridian Health is committed to fostering collaboration between researchers, healthcare professionals, and patients to develop and evaluate cutting-edge therapies and interventions. With a focus on enhancing health outcomes and addressing pressing medical needs, the organization leverages its extensive network of hospitals, specialty care centers, and research facilities to advance clinical knowledge and contribute to the global body of medical science.

Locations

Hackensack, New Jersey, United States

Hackensack, New Jersey, United States

Patients applied

0 patients applied

Trial Officials

Daniel Mansour, MD

Principal Investigator

Hackensack Meridian Health

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials